| Annual · values | 2025 | 2024 |
|---|---|---|
| Operating Cash Flow | -22.86 M USD | -20.09 M USD |
| Depreciation & Amortization | 216000 USD | 206000 USD |
| Stock-Based Compensation | 826000 USD | 156000 USD |
| Capital Expenditures | 90000 USD | 153000 USD |
| Cash Flow from Investing | -90000 USD | -153000 USD |
| Cash Flow from Financing | 23.60 M USD | 15.07 M USD |
| Dividends Paid | — | — |
| Stock Buybacks | — | — |
| Free Cash Flow | -22.95 M USD | -20.24 M USD |
CapsoVision, Inc. is a commercial-stage medical technology company specializing in advanced imaging and artificial intelligence technologies for endoscopy solutions. It focuses on identifying abnormalities in the gastrointestinal tract for diagnostic and screening purposes. The company's core product is the CapsoCam Plus, a single-use capsule endoscope system that provides panoramic visualization of the small-bowel mucosa to detect conditions such as obscure gastrointestinal bleeding and Crohn's disease. Additional offerings include CapsoCam Colon for colon visualization, polyp detection, and measurement, along with CapsoCloud, a cloud-based software-as-a-service platform for video access and download; CapsoAccess for capsule data management; CapsoView for video reading; and CapsoRetrieve, a retrieval kit using a magnetic wand. CapsoVision also provides capsule video reading services. These solutions serve gastrointestinal medical practices, clinics, and hospitals through distributor customers who resell the products. Founded in 2005 and headquartered in Saratoga, California, CapsoVision plays a key role in enhancing non-invasive diagnostic capabilities within the health technology sector.